Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Corticosteroid Sparing Effect of Certolizumab in Crohn's Disease (COSPAR1)

10. juli 2018 opdateret af: UCB Pharma

A Phase IIIb Multicenter, Double-blind, Placebo-controlled,Randomized Trial to Examine the Corticosteroid-sparing Effect of Certolizumab Pegol in Patients With Moderate to Severe Crohn's Disease.

The current study is designed to measure the corticosteroid-sparing effect of certolizumab pegol using a defined schedule of corticosteroid tapering in subjects with moderate to severe Crohn's disease. Subjects had to be in remission (CDAI<=150) and receiving corticosteroids at a dose no higher than 30 mg/day prednisone or equivalent during the week prior to randomization.

Studieoversigt

Status

Afsluttet

Betingelser

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

174

Fase

  • Fase 3

Udvidet adgang

Ledig uden for det kliniske forsøg. Se udvidet adgangsregistrering.

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

  • Canada
    • Alberta
      • Calgary, Alberta, Canada
      • Edmonton, Alberta, Canada
    • British Columbia
      • Abbotsford, British Columbia, Canada
      • Vancouver, British Columbia, Canada
    • Manitoba
      • Winnipeg, Manitoba, Canada
    • Nova Scotia
      • Halifax, Nova Scotia, Canada
    • Ontario
      • London, Ontario, Canada
      • Toronto, Ontario, Canada
    • Saskatchewan
      • Saskatoon, Saskatchewan, Canada
  • Forenede Stater
    • Alabama
      • Birmingham, Alabama, Forenede Stater
      • Montgomery, Alabama, Forenede Stater
    • Arizona
      • Tucson, Arizona, Forenede Stater
    • California
      • La Jolla, California, Forenede Stater
      • Oceanside, California, Forenede Stater
      • Orange, California, Forenede Stater
      • Palo Alto, California, Forenede Stater
      • Roseville, California, Forenede Stater
    • Colorado
      • Golden, Colorado, Forenede Stater
    • Florida
      • Clearwater, Florida, Forenede Stater
      • Gainesville, Florida, Forenede Stater
      • Hialeah, Florida, Forenede Stater
      • Jacksonville, Florida, Forenede Stater
      • North Miami Beach, Florida, Forenede Stater
      • Sarasota, Florida, Forenede Stater
      • Winter Park, Florida, Forenede Stater
    • Georgia
      • Marietta, Georgia, Forenede Stater
      • Savannah, Georgia, Forenede Stater
    • Illinois
      • Chicago, Illinois, Forenede Stater
    • Indiana
      • Bloomington, Indiana, Forenede Stater
    • Kansas
      • Topeka, Kansas, Forenede Stater
    • Kentucky
      • Bowling Green, Kentucky, Forenede Stater
      • Louisville, Kentucky, Forenede Stater
    • Louisiana
      • Metairie, Louisiana, Forenede Stater
    • Maryland
      • Annapolis, Maryland, Forenede Stater
    • Massachusetts
      • Newton, Massachusetts, Forenede Stater
    • Michigan
      • Chesterfield, Michigan, Forenede Stater
      • Dearborn, Michigan, Forenede Stater
      • Troy, Michigan, Forenede Stater
    • Minnesota
      • Rochester, Minnesota, Forenede Stater
    • Mississippi
      • Ocean Springs, Mississippi, Forenede Stater
    • Missouri
      • Kansas City, Missouri, Forenede Stater
      • Mexico, Missouri, Forenede Stater
    • New York
      • New York, New York, Forenede Stater
      • Syracuse, New York, Forenede Stater
    • North Carolina
      • Chapel Hill, North Carolina, Forenede Stater
      • Charlotte, North Carolina, Forenede Stater
      • Raleigh, North Carolina, Forenede Stater
    • Ohio
      • Cincinnati, Ohio, Forenede Stater
      • Cleveland, Ohio, Forenede Stater
      • Dayton, Ohio, Forenede Stater
    • Oklahoma
      • Tulsa, Oklahoma, Forenede Stater
    • South Carolina
      • Columbia, South Carolina, Forenede Stater
    • Tennessee
      • Germantown, Tennessee, Forenede Stater
    • Texas
      • Austin, Texas, Forenede Stater
      • Irving, Texas, Forenede Stater
    • Utah
      • Salt Lake City, Utah, Forenede Stater
    • Vermont
      • Burlington, Vermont, Forenede Stater
    • Virginia
      • Chesapeake, Virginia, Forenede Stater
      • Richmond, Virginia, Forenede Stater
    • Washington
      • Seattle, Washington, Forenede Stater
    • Wisconsin
      • Madison, Wisconsin, Forenede Stater
      • Milwaukee, Wisconsin, Forenede Stater
      • Monroe, Wisconsin, Forenede Stater
  • Tyskland
      • Frankfurt, Tyskland
      • Heidleberg, Tyskland
      • Jena, Tyskland
      • Magdeburg, Tyskland
      • Ulm, Tyskland

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Men and women
  • Age 18 years or older with moderate to severe Crohn's disease (Crohn's Disease Activity Index (CDAI) score of ≥ 220 ≤450)

Exclusion Criteria:

  • Active or draining fistula present at screening
  • Lactating and/or pregnant female subjects
  • A history of any health condition that could potentially interfere with the disease and/or the treatment
  • A history of an adverse reaction to polyethylene glycol (PEG) or a protein medicinal product
  • Any other condition which in the Investigator's judgment would make the patient unsuitable for inclusion in the study
  • History of drug or alcohol abuse in the prior year
  • Receipt of any experimental therapy within or outside a clinical trial in the 3 months prior to Visit 0

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Dobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Placebo komparator: Placebo
Andet: Placebo
Placebo (commercially available sodium chloride 0.9% (preservative free)) provided for subcutaneous injection in single-use vials for administration at Weeks 0, 2, 4 and then every 4 weeks until Week 36. Two vials will be required for each dosing.
Eksperimentel: Certolizumab pegol 400 mg
Biologisk: certolizumab pegol 400 mg
Certolizumab pegol 400 mg provided in solution for subcutaneous injection (2 x 200 mg/mL) in single-use vials for administration at Weeks 0, 2, 4 and then every 4 weeks until Week 36. Two vials will be required for each dosing.
Andre navne:
  • Cimzia
  • CZP
  • CDP870

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Percentage of Subjects Who Have Been Withdrawn From Prednisone or Prednisolone Therapy According to the Corticosteroid Tapering Schedule and Have Remained Off Corticosteroids and in Disease Remission at Week 38
Tidsramme: Week 38
The Crohn's Disease Activity Index (CDAI) is used to quantify the symptoms of subjects with Crohn's disease. A CDAI score of 150 or below indicates disease remission and a score above 450 indicates extremely severe disease.
Week 38

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Percentage of Subjects With Continuous Remission Off Steroids at Week 38
Tidsramme: Week 38
The Crohn's Disease Activity Index (CDAI) is used to quantify the symptoms of subjects with Crohn's disease. A CDAI score of 150 or below indicates disease remission and a score above 450 indicates extremely severe disease. A subject with continuous remission off steroids at Week 38 is a subject in remission (CDAI =< 150) from the visit when he stops taking steroids to Week 38 and is off corticosteroids until Week 38.
Week 38
Cumulative Percentage of Subjects With Relapse/Treatment Failure at Week 38
Tidsramme: Week 38
A subject with relapse/ treatment failure has a Crohn's Disease Activity Index (CDAI) > 150 and an increase in CDAI of >= 70 points versus Week 0. [The CDAI is used to quantify the symptoms of subjects with Crohn's disease. A score of 150 or below indicates disease remission and a score above 450 indicates extremely severe disease.]
Week 38
Time to Relapse/Treatment Failure During the 38-week Double-blind Treatment Period
Tidsramme: During the 38-week double-blind treatment period
A subject with relapse/ treatment failure has a Crohn's Disease Activity Index (CDAI) > 150 and an increase in CDAI of >= 70 points versus Week 0. [The CDAI is used to quantify the symptoms of subjects with Crohn's disease. A score of 150 or below indicates disease remission and a score above 450 indicates extremely severe disease.]
During the 38-week double-blind treatment period
Per-subject Median Weekly Dose of Corticosteroids Over the 38-week Double-blind Treatment Period
Tidsramme: Over the 38-week double-blind treatment period
The median weekly dose of corticosteroids is calculated for each subject, and these per-subject median values are further summarized by treatment group. The mean of the per-subject median doses in each treatment group is presented here.
Over the 38-week double-blind treatment period
Per-subject Cumulative Dose of Corticosteroids Over the 48-week Study Period
Tidsramme: Over the 48-week study period
The cumulative dose of corticosteroids over the 48-week study period is calculated for each subject individually. The mean of these values for each treatment group is presented here.
Over the 48-week study period
Change From the 6-week run-in Period in Per-subject Median Weekly Dose of Corticosteroids Over the 38-week Double-blind Treatment Period
Tidsramme: 6-week run-in period, 38-week double-blind treatment period
The run in period lasted a minimum of 1 week and a maximum of 6 weeks. During this period subjects were treated with any dose or type of systemic corticosteroids the Investigator felt was appropriate. To be eligible for study randomization, subjects must have been in remission (CDAI ≤150 points) and receiving corticosteroids at a dose no higher than 30 mg/day prednisone or equivalent during the week prior to randomization. Subjects who did not meet these criteria were not randomized and were withdrawn from the study.
6-week run-in period, 38-week double-blind treatment period
Crohn's Disease Activity Index (CDAI) Score at Week 38
Tidsramme: Week 38
The Crohn's Disease Activity Index (CDAI) is used to quantify the symptoms of subjects with Crohn's disease. A score of 150 or below indicates disease remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.
Week 38
Change From Baseline in CDAI Score at Week 38
Tidsramme: Week 0, Week 38
The Crohn's Disease Activity Index (CDAI) is used to quantify the symptoms of subjects with Crohn's disease. A score of 150 or below indicates disease remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.
Week 0, Week 38
Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score at Week 38
Tidsramme: Week 38
The total IBDQ score will be derived as the sum of the responses (each ranging from 1 to 7) to all 32 questions on the IBDQ and can therefore range from 32 to 224. A higher score indicates a better quality of life. IBDQ remission is defined as a subject having an IBDQ total score >= 170 points.
Week 38
Change From Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score at Week 38
Tidsramme: Week 0, Week 38
The total IBDQ score will be derived as the sum of the responses (each ranging from 1 to 7) to all 32 questions on the IBDQ and can therefore range from 32 to 224. A higher scores indicates a better quality of life. IBDQ response is defined as an increase from baseline in the IBDQ total score >= 16 points.
Week 0, Week 38

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

UCB Pharma

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Hjælpsomme links

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart

1. november 2006

Primær færdiggørelse (Faktiske)

1. juli 2009

Studieafslutning (Faktiske)

1. juli 2009

Datoer for studieregistrering

Først indsendt

30. juni 2006

Først indsendt, der opfyldte QC-kriterier

6. juli 2006

Først opslået (Skøn)

10. juli 2006

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

9. august 2018

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

10. juli 2018

Sidst verificeret

1. oktober 2010

Mere information

Begreber relateret til denne undersøgelse

Nøgleord

Yderligere relevante MeSH-vilkår

Andre undersøgelses-id-numre

  • C87059
  • 2006-003870-88 (EudraCT nummer)

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner